If you've used Rasagiline (Azilect) or Selegline, we want your feedback.

Safinamide (brand name Onstryv), which was approved in Europe in February 2015 and in the United States in March 2017, is indicated as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD). It can be prescribed to patients experiencing "off" episodes while on a stable dose of levodopa, and its action is similar to Rasagiline (brand name Azilect) and Selegline, in that it is a monoamine oxidase (MAO-B) inhibitor.

At present, Safinamide is being considered for approval in Canada. As part of the drug approval system in Canada, a recommendation is sought from the Canadian Agency for Drugs and Technologies in Health (CADTH) prior to any provincial drug plans considering listing and paying for a new medication. As such, CADTH is interested in obtaining input from a wide range of patients and caregivers.

To assist in achieving a positive recommendation for Safinamide, Parkinson Society British Columbia (PSBC) will file a patient evidence submission for the national review process. If you have used Rasagiline (brand name Azilect) and/or Selegline in the past, we would like to know more about your experience with these drugs.

This survey will collect demographic information from respondents as CADTH prefers to have this information when considering new therapies.

Please only complete this survey if you, or the person you are caring for, has experience with a MAO-B inhibitor drug for the treatment of Parkinson's disease.

The survey will close on Friday, June 7.

Take the Survey